Trevi Therapeutics, Inc. TRVI Enterprise value

Enterprise value at other companies

Merck & Co.MRK

$367.21B+59.3%

SavaraSVRA

$1.11B+127%

Indivior Pharmaceuticals, Inc.INDV

$4.05B+242%

Theravance BiopharmaTBPH

$588.13M+55.1%

LQD

Liquidia CorporationLQDA

$3.11B+184%

Upstream Bio, Inc.UPB

$394.17M+52.4%

FAQ

What is Trevi Therapeutics, Inc.'s enterprise value?

Trevi Therapeutics, Inc. (TRVI) reported enterprise value of $1.51B in Q1 2026.

How has Trevi Therapeutics, Inc.'s enterprise value changed year-over-year?

Trevi Therapeutics, Inc.'s enterprise value increased by 156.6% year-over-year, from $589.71M to $1.51B.

What is the long-term trend for Trevi Therapeutics, Inc.'s enterprise value?

Over 5 years (2020 to 2025), Trevi Therapeutics, Inc.'s enterprise value has grown at a 271.4% compound annual growth rate (CAGR), from $2.25M to $1.59B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.